Shao-Lee Lin
CIK 1725092 · Chief Executive Officer · last filed 2026-07-30
Shao-Lee Lin is a Chief Executive Officer who has filed 27 SEC Form 4 insider transactions across 6 companies since 2018. The most recent filing, for CUE, was dated Jul 30, 2026. Across all open-market trades the lifetime net is −$264.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $17.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$17.10M
6
27
-$264.6K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CUE | Chief Executive Officer | 655,074 | $26.10 | $17.10M | $0 | 4 | 2026-07-30 |
| SRZNW | Director | — | $0.01 | — | $0 | 4 | 2025-05-15 |
| ACELYRIN, Inc. (SLRN) Delisted | Chief Executive Officer | 1,927,272 | $2.27 | $4.37M | -$264.6K | 7 | 2024-04-03 |
| Third Harmonic Bio, Inc. (THRD) Delisted | Director | — | $5.38 | — | $0 | 1 | 2022-10-27 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | — | — | — | $0 | 4 | 2020-09-28 |
| Horizon Therapeutics Public Ltd Co (HZNP) Delisted | EVP, Head of R&D and CSO | 109,668 | $116.30 | $12.75M | $0 | 6 | 2020-01-23 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-30 | CUE | Grant (A) | — | $0 | EDGAR |
| 2026-07-10 | CUE | Grant (A) | +327,537 | $0 | EDGAR |
| 2026-06-03 | CUE | Buy (P) | — | $0 | EDGAR |
| 2026-05-07 | CUE | Grant (A) | +327,537 | $0 | EDGAR |
| 2025-05-15 | SRZNW | Grant (A) | — | $0 | EDGAR |
| 2024-06-06 | SRZNW | Grant (A) | — | $0 | EDGAR |
| 2024-04-03 | ACELYRIN, Inc. (SLRN) Delisted | Sell (S) | −9,961 | -$66.0K | EDGAR |
| 2024-02-22 | ACELYRIN, Inc. (SLRN) Delisted | Sell (S) | −15,701 | -$119.4K | EDGAR |
| 2024-01-11 | ACELYRIN, Inc. (SLRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-04 | ACELYRIN, Inc. (SLRN) Delisted | Sell (S) | −10,691 | -$79.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.